Matches in SemOpenAlex for { <https://semopenalex.org/work/W1483647539> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W1483647539 endingPage "5" @default.
- W1483647539 startingPage "1903" @default.
- W1483647539 abstract ". To investigate whether features associated with severe rheumatoid arthritis (RA) are predictive of adverse drug reactions (ADR) to gold salts, independent of HLA-DR3 status.A cohort of patients with RA (n = 41) who developed thrombocytopenia (platelets < 100 10(6)/l) or proteinuria (> 1.0 g/24 h) upon treatment with gold sodium thiomalate was identified from patient records and matched for age, sex, and disease duration with 41 RA controls treated with gold without development of ADR. A second group of 161 random RA patients that had received gold therapy for at least as long without development of an ADR was also compared. All patients were typed for HLA-DRB1, and the presence of rheumatoid factor (RF), antinuclear antibodies (ANA), and nodules before initiation of therapy was recorded. Association of clinical or genetic factors with ADR was investigated using the McNemar test and logistic regression analysis.Patients with ADR were more likely to have nodular disease than their matched controls (51.3% vs 25.6%; odds ratio, OR = 3.0, p = 0.02) and more likely to be HLA-DR3 positive (41.2% vs 17.6%; OR = 3.0, p = 0.045). No difference between the groups was found for RF or ANA. Nodular disease was associated with development of ADR independently of HLA-DR3, although a combination of both factors significantly increased the likelihood of an ADR.Our data suggest that nodular disease may be a predictor of gold-induced ADR independent of HLA-DR3." @default.
- W1483647539 created "2016-06-24" @default.
- W1483647539 creator A5010330353 @default.
- W1483647539 creator A5027121029 @default.
- W1483647539 creator A5047695443 @default.
- W1483647539 creator A5050182037 @default.
- W1483647539 creator A5052406633 @default.
- W1483647539 creator A5058896231 @default.
- W1483647539 creator A5069243083 @default.
- W1483647539 creator A5069396146 @default.
- W1483647539 creator A5086720624 @default.
- W1483647539 date "2004-10-01" @default.
- W1483647539 modified "2023-09-24" @default.
- W1483647539 title "Can gold therapy be used more safely in rheumatoid arthritis? Adverse drug reactions are more likely in patients with nodular disease, independent of HLA-DR3 status." @default.
- W1483647539 cites W1821005191 @default.
- W1483647539 cites W2005331490 @default.
- W1483647539 cites W2067210148 @default.
- W1483647539 cites W2340851041 @default.
- W1483647539 cites W2398201152 @default.
- W1483647539 cites W2416747102 @default.
- W1483647539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15468351" @default.
- W1483647539 hasPublicationYear "2004" @default.
- W1483647539 type Work @default.
- W1483647539 sameAs 1483647539 @default.
- W1483647539 citedByCount "3" @default.
- W1483647539 crossrefType "journal-article" @default.
- W1483647539 hasAuthorship W1483647539A5010330353 @default.
- W1483647539 hasAuthorship W1483647539A5027121029 @default.
- W1483647539 hasAuthorship W1483647539A5047695443 @default.
- W1483647539 hasAuthorship W1483647539A5050182037 @default.
- W1483647539 hasAuthorship W1483647539A5052406633 @default.
- W1483647539 hasAuthorship W1483647539A5058896231 @default.
- W1483647539 hasAuthorship W1483647539A5069243083 @default.
- W1483647539 hasAuthorship W1483647539A5069396146 @default.
- W1483647539 hasAuthorship W1483647539A5086720624 @default.
- W1483647539 hasConcept C126322002 @default.
- W1483647539 hasConcept C149443304 @default.
- W1483647539 hasConcept C156957248 @default.
- W1483647539 hasConcept C159654299 @default.
- W1483647539 hasConcept C163764329 @default.
- W1483647539 hasConcept C203014093 @default.
- W1483647539 hasConcept C2776232647 @default.
- W1483647539 hasConcept C2777575956 @default.
- W1483647539 hasConcept C71924100 @default.
- W1483647539 hasConcept C72563966 @default.
- W1483647539 hasConcept C90924648 @default.
- W1483647539 hasConceptScore W1483647539C126322002 @default.
- W1483647539 hasConceptScore W1483647539C149443304 @default.
- W1483647539 hasConceptScore W1483647539C156957248 @default.
- W1483647539 hasConceptScore W1483647539C159654299 @default.
- W1483647539 hasConceptScore W1483647539C163764329 @default.
- W1483647539 hasConceptScore W1483647539C203014093 @default.
- W1483647539 hasConceptScore W1483647539C2776232647 @default.
- W1483647539 hasConceptScore W1483647539C2777575956 @default.
- W1483647539 hasConceptScore W1483647539C71924100 @default.
- W1483647539 hasConceptScore W1483647539C72563966 @default.
- W1483647539 hasConceptScore W1483647539C90924648 @default.
- W1483647539 hasIssue "10" @default.
- W1483647539 hasLocation W14836475391 @default.
- W1483647539 hasOpenAccess W1483647539 @default.
- W1483647539 hasPrimaryLocation W14836475391 @default.
- W1483647539 hasVolume "31" @default.
- W1483647539 isParatext "false" @default.
- W1483647539 isRetracted "false" @default.
- W1483647539 magId "1483647539" @default.
- W1483647539 workType "article" @default.